Article ; Online: Prognostic and predictive biomarkers in melanoma.
2023 Volume 56, Issue 2, Page(s) 259–273
Abstract: Biomarkers help to inform the clinical management of patients with melanoma. For patients with clinically localised primary melanoma, biomarkers can help to predict post-surgical outcome (including via the use of risk prediction tools), better select ... ...
Abstract | Biomarkers help to inform the clinical management of patients with melanoma. For patients with clinically localised primary melanoma, biomarkers can help to predict post-surgical outcome (including via the use of risk prediction tools), better select patients for sentinel lymph node biopsy, and tailor catch-all follow-up protocols to the individual. Systemic drug treatments, including immune checkpoint inhibitor (ICI) therapies and BRAF-targeted therapies, have radically improved the prognosis of metastatic (stage III and IV) cutaneous melanoma patients, and also shown benefit in the earlier setting of stage IIB/C primary melanoma. Unfortunately, a response is far from guaranteed. Here, we review clinically relevant, established, and emerging, prognostic, and predictive pathological biomarkers that refine clinical decision-making in primary and metastatic melanoma patients. Gene expression profile assays and nomograms are emerging tools for prognostication and sentinel lymph node risk prediction in primary melanoma patients. Biomarkers incorporated into clinical practice guidelines include BRAF V600 mutations for the use of targeted therapies in metastatic cutaneous melanoma, and the HLA-A∗02:01 allele for the use of a bispecific fusion protein in metastatic uveal melanoma. Several predictive biomarkers have been proposed for ICI therapies but have not been incorporated into Australian clinical practice guidelines. Further research, validation, and assessment of clinical utility is required before more prognostic and predictive biomarkers are fluidly integrated into routine care. |
---|---|
MeSH term(s) | Humans ; Melanoma/diagnosis ; Melanoma/genetics ; Melanoma/drug therapy ; Skin Neoplasms/diagnosis ; Skin Neoplasms/genetics ; Skin Neoplasms/pathology ; Prognosis ; Proto-Oncogene Proteins B-raf/genetics ; Australia ; Biomarkers, Tumor/genetics ; Sentinel Lymph Node Biopsy |
Chemical Substances | Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Biomarkers, Tumor |
Language | English |
Publishing date | 2023-12-20 |
Publishing country | England |
Document type | Review ; Journal Article |
ZDB-ID | 7085-3 |
ISSN | 1465-3931 ; 0031-3025 |
ISSN (online) | 1465-3931 |
ISSN | 0031-3025 |
DOI | 10.1016/j.pathol.2023.11.004 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 723: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.